Openings for Freshers in JAMP pharma R&D Centre (ARD & FRD) and Openings for Associate Scientist in Pfizer

Openings for Freshers in JAMP pharma R&D Centre (ARD & FRD) and Openings for Associate Scientist in Pfizer

 Pfizer Logo

About the Company : 

The company established in 1988, and more than 180 OTC products and have head quarters in Canada with the bio similar in Canada. The firm is generic based product and is scope in cosmetic beauty, personal care and is one of the fastest growing pharmaceutical company. The firm have highly talented colleagues, capability in producing new products launch. 

About the Job 

We are #hiring #freshers at #Jamp Pharma - R & D Center #Hyderabad

Looking for Trainee Roles - Formulation Development & Analytical Development - R & D

Qualification: M.Pharm (Pharmaceutical Analysis) / M.Sc (Analytical Chemistry) 


-Male candidates are eligible.

-Should be flexible working in rotational shifts.

Interested candidates may please share your resume to:

 [email protected]

About Pfizer : 

One of the major contributor of medicines globally ranking in top 10 pharma companies. The industry equipped with more than 1500 scientists with more than 5 million testing labs globally and over 36 clinical trials before the first perception. In the area of biotechnological medicine  with 25000 clinical researchers testing every day world wide. 
The company has located its head quarters in New York with the rank 57 in fortune 500 companies, founded in 1849, which is 170 years ago. Form have joint ventures with GSK and Mylan for improving the quality of medicines.
Large portfolio including branded and generics with products listed from A to Z. Applies rare diseases research to unveil the new therapy treatment, more than 30 million people in USA and 350 million globally uses the medicines for rare disease treatments. Several hematological and neurological rare disease therapies are in research phase. Gene therapy is one of the promising and rapidly developing portfolio in the companies profile, placing genetically corrected copies to patients cells. Having collaboration with Spark  therapeutics and investigating SPK-9001. As a snapshot  35 projects are in Phase 1, 34 are being in phase 2, 23 in phase 3, 9 went for registration with a total of 101 (metrics as of July 2019)  
Constantly providing medicines in the areas of Hospital (anti infectives), oncology, anti inflammatory, oncology, rare diseases, biosimilars, vaccines and new molecular entities.

Experience: MSc with 1-3 years 

Experience in literature search for alternative route of synthesis for intermediates, API and impurities